Cancer Drugs FAQs

Transitional support is provided to allow policyholders on a course of cancer drug treatment from 1 Jan 2023 to 31 Mar 2023*, and whose policies are renewing between 1 Apr 2023 and 30 Sep 2023, to have sufficient time to adjust to the changes. Those eligible for transitional support will continue to receive their current coverage until 30 Sep 2023.

*Where at least one IP claim is made for an outpatient or inpatient cancer drug treatment administered between 1 Jan 2023 to 31 Mar 2023.

If you are undergoing a treatment that is not on the CDL, you may wish to discuss with your doctor(s) whether there are suitable alternative treatments on the CDL. Please refer to Q15 if switching to a CDL treatment is not feasible.

If switching to a CDL treatment is not feasible, there is support available for those facing difficulties.

• If you are a subsidised patient, you can approach a Medical Social Worker (MSW) in your public healthcare institution (PHI) for financial assistance such as MediFund.
  
  
• If you are a non-subsidised patient in a PHI or a patient in a private medical institution, you can approach your doctor to refer you to subsidised care in a PHI, where financial assistance may be available. The PHI’s medical team will review your treatment plan and provide financial counselling (e.g. eligibility for subsidies) before you decide whether to proceed.